{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055667","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.428253+00:00","generated_at":"2026-06-02T12:46:18.089316+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Surrozen Q1 net loss $8.8M; cash $27.3M; SZN-043 Phase 1b enrollment starts Q2 2024","bullets":["Cash $27.3M at Mar 31; proforma $43.2M after April financing. Net loss $8.8M vs $14.3M YoY.","R&D expense $5.2M (down 36% YoY); G&A $3.9M (down 26% YoY) reflecting 2023 restructuring.","SZN-043 Phase 1a completed; Phase 1b enrollment to begin Q2 2024; proof-of-concept data expected H1 2025.","Potential $10M milestone from Boehringer Ingelheim if lead Fzd-4 Wnt agonist candidate nominated in 2024.","Preclinical data at ARVO on Wnt mimetic for corneal dystrophies; publication on pulmonary fibrosis in Respiratory Research."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055667","json":"https://secwatch.observer/filing/0000950170-24-055667.json","markdown":"https://secwatch.observer/filing/0000950170-24-055667.md","text":"https://secwatch.observer/filing/0000950170-24-055667.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000095017024055667/0000950170-24-055667-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000095017024055667/srzn-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T12:46:18.089316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e124d8030b67600a2fb83f9099daed69ba33ea1","claim":"Surrozen, Inc./DE reported the quarter ended March 31, 2024 results: net income $8.8 million.","evidence_excerpt":"Net loss for the first quarter ended March 31, 2024 was $8.8 million, as compared to $14.3 million for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824893/000095017024055667/0000950170-24-055667-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"$8.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}